212 related articles for article (PubMed ID: 31010082)
1. MSC.sTRAIL Has Better Efficacy than MSC.FL-TRAIL and in Combination with AKTi Blocks Pro-Metastatic Cytokine Production in Prostate Cancer Cells.
Mohr A; Chu T; Brooke GN; Zwacka RM
Cancers (Basel); 2019 Apr; 11(4):. PubMed ID: 31010082
[TBL] [Abstract][Full Text] [Related]
2. Delivery of sTRAIL variants by MSCs in combination with cytotoxic drug treatment leads to p53-independent enhanced antitumor effects.
Yu R; Deedigan L; Albarenque SM; Mohr A; Zwacka RM
Cell Death Dis; 2013 Feb; 4(2):e503. PubMed ID: 23429289
[TBL] [Abstract][Full Text] [Related]
3. Impact of soluble tumor necrosis factor-related apoptosis-inducing ligand released by engineered adipose mesenchymal stromal cells on white blood cells.
Casari G; Dall'Ora M; Melandri A; Masciale V; Chiavelli C; Prapa M; Neri G; Spano MC; Murgia A; D'Esposito A; Baschieri MC; Ceccherelli GB; Dominici M; Grisendi G
Cytotherapy; 2023 Jun; 25(6):605-614. PubMed ID: 37012089
[TBL] [Abstract][Full Text] [Related]
4. Targeting of XIAP combined with systemic mesenchymal stem cell-mediated delivery of sTRAIL ligand inhibits metastatic growth of pancreatic carcinoma cells.
Mohr A; Albarenque SM; Deedigan L; Yu R; Reidy M; Fulda S; Zwacka RM
Stem Cells; 2010 Nov; 28(11):2109-20. PubMed ID: 20882532
[TBL] [Abstract][Full Text] [Related]
5. Human Umbilical Cord MSC Delivered-Soluble TRAIL Inhibits the Proliferation and Promotes Apoptosis of B-ALL Cell In Vitro and In Vivo.
Chen F; Zhong X; Dai Q; Li K; Zhang W; Wang J; Zhao Y; Shen J; Xiao Z; Xing H; Li J
Pharmaceuticals (Basel); 2022 Nov; 15(11):. PubMed ID: 36422522
[TBL] [Abstract][Full Text] [Related]
6. Engineered sTRAIL-armed MSCs overcome STING deficiency to enhance the therapeutic efficacy of radiotherapy for immune checkpoint blockade.
Huang KC; Chiang SF; Chang HY; Chen WT; Yang PC; Chen TW; Liang JA; Shiau AC; Ke TW; Clifford Chao KS
Cell Death Dis; 2022 Jul; 13(7):610. PubMed ID: 35835756
[TBL] [Abstract][Full Text] [Related]
7. Histone deacetylase inhibitor panobinostat potentiates the anti-cancer effects of mesenchymal stem cell-based sTRAIL gene therapy against malignant glioma.
Choi SA; Lee C; Kwak PA; Park CK; Wang KC; Phi JH; Lee JY; Chong S; Kim SK
Cancer Lett; 2019 Feb; 442():161-169. PubMed ID: 30367915
[TBL] [Abstract][Full Text] [Related]
8. Preclinical Biosafety Evaluation of Genetically Modified Human Adipose Tissue-Derived Mesenchymal Stem Cells for Clinical Applications to Brainstem Glioma.
Choi SA; Yun JW; Joo KM; Lee JY; Kwak PA; Lee YE; You JR; Kwon E; Kim WH; Wang KC; Phi JH; Kang BC; Kim SK
Stem Cells Dev; 2016 Jun; 25(12):897-908. PubMed ID: 27151205
[TBL] [Abstract][Full Text] [Related]
9. Mesenchymal Stem Cells Genetically Modified by Lentivirus-Express Soluble TRAIL and Interleukin-12 Inhibit Growth and Reduced Metastasis-Relate Changes in Lymphoma Mice Model.
Quiroz-Reyes AG; Gonzalez-Villarreal CA; Limon-Flores AY; Delgado-Gonzalez P; Martinez-Rodriguez HG; Said-Fernandez SL; Soto-Dominguez A; Rivas-Estilla AM; Islas JF; Molina-De la Garza JF; Garza-Treviño EN
Biomedicines; 2023 Feb; 11(2):. PubMed ID: 36831131
[TBL] [Abstract][Full Text] [Related]
10. Human umbilical cord mesenchymal stem cells as vehicles of CD20-specific TRAIL fusion protein delivery: a double-target therapy against non-Hodgkin's lymphoma.
Yan C; Li S; Li Z; Peng H; Yuan X; Jiang L; Zhang Y; Fan D; Hu X; Yang M; Xiong D
Mol Pharm; 2013 Jan; 10(1):142-51. PubMed ID: 23121392
[TBL] [Abstract][Full Text] [Related]
11. Human umbilical cord mesenchymal stem cells delivering sTRAIL home to lung cancer mediated by MCP-1/CCR2 axis and exhibit antitumor effects.
Yan C; Song X; Yu W; Wei F; Li H; Lv M; Zhang X; Ren X
Tumour Biol; 2016 Jun; 37(6):8425-35. PubMed ID: 26733169
[TBL] [Abstract][Full Text] [Related]
12. Improved Anti-Tumor Activity of Novel Highly Bioactive Liposome-Bound TRAIL in Breast Cancer Cells.
De Miguel D; Gallego-Lleyda A; Ayuso JM; Pawlak A; Conde B; Ochoa I; Fernández LJ; Anel A; Martinez-Lostao L
Recent Pat Anticancer Drug Discov; 2016; 11(2):197-214. PubMed ID: 26924736
[TBL] [Abstract][Full Text] [Related]
13. [Interleukin-12 enhanced tumor necrosis factor related apoptosis-inducing ligand TRAIL-induced apoptosis in human hepatocellular carcinoma by inhibiting expression of survivin].
He SQ; Chen Y; Chen XP; Zhang WG; Wang HP; Zhang BX
Zhonghua Wai Ke Za Zhi; 2003 Jun; 41(6):453-7. PubMed ID: 12895357
[TBL] [Abstract][Full Text] [Related]
14. sTRAIL coupled to liposomes improves its pharmacokinetic profile and overcomes neuroblastoma tumour resistance in combination with Bortezomib.
Loi M; Becherini P; Emionite L; Giacomini A; Cossu I; Destefanis E; Brignole C; Di Paolo D; Piaggio F; Perri P; Cilli M; Pastorino F; Ponzoni M
J Control Release; 2014 Oct; 192():157-66. PubMed ID: 25041999
[TBL] [Abstract][Full Text] [Related]
15. Mesenchymal Stem Cell Expressing TRAIL as Targeted Therapy against Sensitised Tumour.
Fakiruddin KS; Ghazalli N; Lim MN; Zakaria Z; Abdullah S
Int J Mol Sci; 2018 Jul; 19(8):. PubMed ID: 30060445
[TBL] [Abstract][Full Text] [Related]
16. Anti-GD2 CAR MSCs against metastatic Ewing's sarcoma.
Golinelli G; Grisendi G; Dall'Ora M; Casari G; Spano C; Talami R; Banchelli F; Prapa M; Chiavelli C; Rossignoli F; Candini O; D'Amico R; Nasi M; Cossarizza A; Casarini L; Dominici M
Transl Oncol; 2022 Jan; 15(1):101240. PubMed ID: 34649148
[TBL] [Abstract][Full Text] [Related]
17. High-order TRAIL oligomer formation in TRAIL-coated lipid nanoparticles enhances DR5 cross-linking and increases antitumour effect against colon cancer.
De Miguel D; Gallego-Lleyda A; Ayuso JM; Pejenaute-Ochoa D; Jarauta V; Marzo I; Fernández LJ; Ochoa I; Conde B; Anel A; Martinez-Lostao L
Cancer Lett; 2016 Dec; 383(2):250-260. PubMed ID: 27725224
[TBL] [Abstract][Full Text] [Related]
18. Treatment with IFNalpha in vivo up-regulates serum-soluble TNF-related apoptosis inducing ligand (sTRAIL) levels and TRAIL mRNA expressions in neutrophils in chronic myelogenous leukemia patients.
Tanaka H; Ito T; Kyo T; Kimura A
Eur J Haematol; 2007 May; 78(5):389-98. PubMed ID: 17432976
[TBL] [Abstract][Full Text] [Related]
19. Oxaliplatin Enhances the Apoptotic Effect of Mesenchymal Stem Cells, Delivering Soluble TRAIL in Chemoresistant Colorectal Cancer.
Quiroz-Reyes AG; Delgado-González P; Islas JF; Soto-Domínguez A; González-Villarreal CA; Padilla-Rivas GR; Garza-Treviño EN
Pharmaceuticals (Basel); 2023 Oct; 16(10):. PubMed ID: 37895919
[TBL] [Abstract][Full Text] [Related]
20. Enhanced inhibition of tumor growth using TRAIL-overexpressing adipose-derived stem cells in combination with the chemotherapeutic agent CPT-11 in castration-resistant prostate cancer.
Kim JH; Oh E; Han YS; Lee SH; Song YS
Prostate Int; 2021 Mar; 9(1):31-41. PubMed ID: 33912512
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
